Bortezomib With or Without Hormone Therapy in Treating Patients With Relapsed Prostate Cancer

Stopped early · Phase 2

Conditions studied: Prostate Cancer

In brief

RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Androgens can cause the growth of prostate cancer cells. Drugs, such as goserelin, leuprolide, flutamide, or bicalutamide, may stop the adrenal glands from making androgens. Giving bortezomib with hormone therapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving bortezomib with or without hormone therapy works in treating patients with relapsed prostate cancer.

Key facts

Study ID

NCT00103376

Run by

Medical University of South Carolina

People needed

23

Starts

2004-10-01

Expected to finish

2011-06-01

Last updated by the study team

2018-11-05

Who can join

Age: 18 and older, up to 120. Sex: male. Healthy volunteers: not accepted.

Where it is running

• Loma Linda University Cancer Institute at Loma Linda University Medical Center — Loma Linda, California, United States
• Hollings Cancer Center at Medical University of South Carolina — Charleston, South Carolina, United States
• South Carolina Oncology Associates, PA — Columbia, South Carolina, United States
• Gibbs Regional Cancer Center at Spartanburg Regional Medical Center — Spartanburg, South Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.